Astrazeneca gets a win for its SGLT2 in heart failure irrespective of diabetes status, but Lilly and Boehringer’s Jardiance isn’t far behind.
Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Success for Lynparza in first-line ovarian cancer, regardless of BRCA mutation status, could see Astrazeneca’s drug regain the upper hand against Glaxosmithkline’s…
Positive data should pave the way for ripretinib’s approval in fourth-line GIST, but investors are already eyeing a bigger opportunity.
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
In blaming bempegaldesleukin’s falling efficacy on poor manufacturing Nektar has alarmed investors even more.